Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one agent shown to shrink tumors in patients whose disease had resisted every standard therapy. The findings span different treatment strategies, from targeted protein degradation to immune-boosting injections and radioactive therapies, and they collectively signal a busy period of innovation for a cancer that kills hundreds of thousands of men worldwide each year. While none of these drugs is ready for widespread use, the early data offer concrete reasons for cautious optimism.
A Drug That Degrades the Androgen Receptor
Among the most closely watched experimental agents is BMS-986365, also known as CC-94676, a dual androgen receptor ligand-directed degrader and antagonist. Rather than simply blocking the androgen receptor, the way conventional hormone therapies do, BMS-986365 is designed to physically destroy the receptor protein inside cancer cells. That distinction matters because many advanced prostate cancers eventually find ways to reactivate androgen signaling even when standard blockers are present, a condition known as metastatic castration-resistant prostate cancer, or mCRPC. Laboratory and early clinical data describing this mechanism have been detailed in a peer‑reviewed report focused on the drug’s dual action.
The drug entered human testing through a first‑in‑human trial that enrolled heavily pretreated patients with mCRPC. In that study, participants had typically exhausted standard hormone therapies, chemotherapy, and in some cases targeted radiotherapy, leaving few remaining options. The design followed a familiar pattern for early oncology trials: a dose‑escalation phase to establish safety and a recommended dose, followed by expansion cohorts to explore signs of activity in specific patient subsets. Key endpoints included prostate‑specific antigen (PSA) declines of at least 50%, radiographic tumor shrinkage on imaging scans, and overall tolerability.
What makes this approach analytically interesting is its dual mechanism. Most prior drugs in the androgen receptor space are pure antagonists that sit in the receptor’s binding pocket and prevent hormones from activating it. By combining antagonism with targeted degradation, BMS-986365 aims to eliminate a key escape route that tumors exploit, including mutations or splice variants that make the receptor harder to block. If the receptor is destroyed rather than merely occupied, cancer cells lose a critical growth signal. The published clinical analysis reported measurable PSA responses and radiographic tumor regressions in a subset of patients who had already failed multiple lines of treatment, along with a safety profile that researchers deemed manageable for further development.
Still, the early data come with caveats. Phase I trials are not designed to prove survival benefits, and response rates can look impressive in small cohorts without necessarily translating into long‑term disease control. Investigators emphasized the need for randomized studies comparing BMS-986365 against existing standards or in combination regimens. Even so, the ability to induce responses in men whose tumors had progressed on nearly every available therapy suggests that targeted receptor degradation could become an important pillar of future prostate cancer treatment.
Immune-Boosting Injections Before Surgery
A separate line of research is testing whether activating the immune system inside a prostate tumor before surgery can change the disease’s trajectory. Investigators at Mount Sinai conducted a phase I trial using intratumoral injections of poly‑ICLC, a synthetic molecule that mimics viral RNA and triggers a strong immune response at the injection site. The trial, which enrolled men with localized, intermediate‑to‑high‑risk prostate cancer awaiting radical prostatectomy, is documented on a federal registry that outlines its neoadjuvant design and eligibility criteria.
The logic behind this approach challenges a common assumption in prostate cancer treatment. Prostate tumors are often described as immunologically “cold,” meaning they attract relatively few immune cells and tend to resist immunotherapy. By injecting an immune stimulant directly into the tumor before removing it, researchers hoped to convert the tumor into a training ground for T cells and other components of the immune system. Results from the trial were detailed in a Med journal article that evaluated safety, feasibility, and immune changes in both the injected tumor tissue and peripheral blood.
In that report, investigators found that the injections were generally well tolerated, with side effects such as transient flu‑like symptoms aligning with the expected immune activation. Analysis of the surgical specimens showed increased infiltration of immune cells and upregulation of inflammatory markers in many patients, suggesting that the local stimulus had successfully “heated up” the tumor microenvironment. While the study was too small and too early to demonstrate a clear impact on long‑term recurrence, it established that presurgical intratumoral immunotherapy is feasible in prostate cancer and can induce measurable biological changes.
This presurgical, or neoadjuvant, immunotherapy concept is still in its infancy for prostate cancer, but it is beginning to echo strategies used in melanoma and certain breast cancers, where immune‑based treatments before surgery have improved outcomes. If injecting a single tumor site can prime the immune system to recognize and attack cancer cells elsewhere in the body, the implications would extend well beyond the operating room. That systemic potential is underscored by other early‑phase work in solid tumors, including trials in which localized injections of experimental agents have led to regression of untreated lesions at distant sites, hinting at a whole‑body immune awakening.
Bispecific Antibodies and Targeted Radiation
Other experimental programs are attacking treatment‑resistant prostate cancer from different angles. REGN5678, a bispecific antibody targeting prostate‑specific membrane antigen (PSMA) on tumor cells and the co‑stimulatory receptor CD28 on T cells, is being studied in a phase 1/2 study both alone and in combination with the checkpoint inhibitor cemiplimab. By physically linking a tumor‑associated antigen with a powerful activation signal on immune cells, REGN5678 aims to wake up T cells that the tumor has rendered inert, potentially overcoming one of the major obstacles in prostate cancer immunotherapy.
Early presentations from this program have highlighted the delicate balance between efficacy and safety. Strong T‑cell activation can drive tumor killing but also risks serious inflammatory toxicities if not tightly controlled. The trial’s multi‑arm design allows investigators to explore different dose levels and combinations, searching for a therapeutic window in which antitumor activity is maximized while immune‑related side effects remain manageable. Because PSMA is also expressed at low levels in some normal tissues, careful monitoring for off‑tumor effects is a key part of the study.
Alongside bispecific antibodies, targeted radiation remains a major focus of innovation. One approach uses small molecules or antibodies that bind PSMA to deliver radioactive payloads directly to prostate cancer cells. A recent phase I study of a radioligand therapy in heavily pretreated mCRPC patients, described in an open‑access clinical report, demonstrated that such agents can shrink tumors and lower PSA levels even after multiple prior therapies have failed. In that trial, many participants experienced partial responses or stable disease, and the main side effects involved manageable levels of bone marrow suppression and fatigue.
These results build on the broader success of PSMA‑targeted radiotherapies, which have already entered standard practice in some settings and are now being refined with new isotopes, dosing schedules, and combination strategies. Researchers are particularly interested in pairing radioligand therapy with agents that either sensitize tumor cells to radiation damage or boost immune recognition of dying cancer cells. The goal is to convert temporary tumor shrinkage into deeper and more durable remissions.
A Rapidly Evolving Landscape
Viewed together, these experimental efforts illustrate how quickly the therapeutic landscape for advanced prostate cancer is evolving. BMS-986365 exemplifies a new generation of precision hormone therapies that go beyond receptor blockade to actual protein removal. Intratumoral poly‑ICLC injections test whether even “cold” tumors can be turned into immunologic training grounds when stimulated in the right way. Bispecific antibodies such as REGN5678 attempt to hard‑wire the connection between tumor cells and T‑cell activation, while PSMA‑directed radioligand therapies deliver potent radiation directly to malignant tissue.
For patients and clinicians, the immediate takeaway is not that any one of these drugs is a guaranteed breakthrough, but that multiple, mechanistically distinct strategies are showing enough promise to justify larger and more definitive trials. Each approach carries its own risks and uncertainties, from immune‑related toxicities to the possibility that tumors will eventually find new escape routes. Yet the diversity of tactics (degradation, immune stimulation, bispecific engagement, and targeted radiation) reduces the field’s reliance on any single pathway.
The next few years will determine which of these candidates can move from early‑phase excitement to proven clinical benefit. Larger randomized studies will need to show not only that tumors shrink on scans or PSA levels fall, but that patients live longer and maintain a good quality of life. Regulators and health systems will also face questions about how to sequence or combine these therapies and how to ensure access if high‑tech treatments carry high price tags.
For now, the emerging data offer a cautiously hopeful message, even in a cancer type long considered stubbornly resistant to immune attack and prone to outsmarting hormone therapies, new biological insights are yielding tangible clinical signals. If ongoing trials confirm and extend these early findings, the next generation of prostate cancer drugs may give patients with the hardest‑to‑treat disease more time and more options than ever before.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
